Loading…

Kardigan, Inc.KARDCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops therapies for cardiovascular disease; a recently formed biotech backed by major venture investors.

Mkt cap
$1.15B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$6.56M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-160.6 pp
WACC 19.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$12.32
1D-6.6%
1W-21.4%
1M-8.8%
3M-39.2%
6Mn/a
YTDn/a
1Yn/a
ATR %10.3%
52w lowhigh54.4% off high

What Kardigan does

Develops therapies for cardiovascular disease; a recently formed biotech backed by major venture investors.

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Cardiovascular disease therapeutics

Moat: none

Headquarters: United States · Employees: 210

Kardigan at a glance

Size Kardigan (KARD) is a United States Health Care company (Biotechnology) with a market value of $1.15B, the 2144th largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.32 on 18 Nov 2026.

Capital Return on invested capital runs 160.6 points below its cost of capital (19.5% WACC).

Short interest Short interest is 6.1% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Kardigan financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$5.74M-$357,000
EBITDAn/a-$197M-$96.3M
Net incomen/a-$192M-$88.7M
Free cash flown/a-$156M-$20.6M
Capital expendituren/a$5.14M$1.80M
Total debt$12.7M$13.8M$16.8M

Quarterly statements and history in the cockpit →

Kardigan competitors and peer comparison

How Kardigan compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kardigan against its 20 peers (data as of 18 Nov 2026)
MeasureKARDPeer medianRank in peer set
1-month return-8.8%-8.6%10th lowest of 21
Distance from 52-week high-54.4%-45.0%6th lowest of 21
ROIC minus cost of capital-160.6 pp-7.7 pplowest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a

Questions

Which companies are Kardigan's closest peers?
The cockpit's peer set: COMPASS Pathways Plc Sponsored ADR (CMPS), Akums Drugs and Pharmaceuticals (AKUMS.NS), Vor Biopharma (VOR), Mineralys Therapeutics (MLYS), Liaoning Chengda Biotechnology (688739.SS), Jade Biosciences (JBIO), Pacific Shuanglin Bio-pharmacy (000403.SZ), Duality Biotherapeutics (9606.HK).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.